Figure 3.

In Vivo Imaging, Ophthalmic Examinations, and Histopathology in AAV2-CatCh-Injected NHPs

(A) Fluorescence fundus images of NHP1 injected with low-dose (left) and high-dose (center) AAV2-SNCG-CatCh-GFP, respectively. OCT scan of the high-dose eye. Images were obtained at 2 months post-injection. Fluorescence around the fovea (white arrow) is only visible in the high-dose-injected left eye. Scale bars represent 500 μm. (B) Uveitis and the level of vitreous haze scores for eyes from all 10 NHPs that received low-dose (10¹¹ vg), mid-dose (5 × 10¹¹ vg), and high-dose (10¹² vg) injections of AAV2 encoding CatCh under SNCG or CMV promoters. (C) Histo-pathological examination of the eye from NHP3 with a mid-dose injection of AAV2-SNCG-CatCh at 3 months post-injection [eye indicated with a white arrow in (B)]. Retinal slice across the vertical meridian of the eye imaged at a resolution of ×40. Absence of detectable lymphocytes, macrophages, or damage to ocular structures in the trabecular meshwork, ciliary body, optic nerve, iris, and retina on magnified areas.